J.P. Morgan: Maintains GENSCRIPT BIO (01548) "Overweight" rating, target price HK$41

J.P. Morgan released a research report stating that Eli Lilly (LLY.US) announced a TuneLab collaboration agreement with GENSCRIPT BIO (01548) and others. The bank maintains its "Overweight" rating on GenScript and a target price of HK$41. Under the agreement, GenScript will provide wet lab services to TuneLab member companies, including gene synthesis, protein expression, purification, and testing under standardized protocols, helping to translate AI-generated drug candidates into experimental results. The bank believes this will help strengthen GenScript's leading position in the AI-driven drug discovery (AIDD) ecosystem.